EA200901473A1 - Внутривенные и пероральные лекарственные формы прямого и обратимого ингибитора p2y12 - Google Patents

Внутривенные и пероральные лекарственные формы прямого и обратимого ингибитора p2y12

Info

Publication number
EA200901473A1
EA200901473A1 EA200901473A EA200901473A EA200901473A1 EA 200901473 A1 EA200901473 A1 EA 200901473A1 EA 200901473 A EA200901473 A EA 200901473A EA 200901473 A EA200901473 A EA 200901473A EA 200901473 A1 EA200901473 A1 EA 200901473A1
Authority
EA
Eurasian Patent Office
Prior art keywords
industrial
direct
oral drug
drug forms
reversible inhibitor
Prior art date
Application number
EA200901473A
Other languages
English (en)
Inventor
Роберт М. Скарбору
Даниел Д. Гретлер
Памела Б. Конли
Патрик Андре
Ативат Хутчалеелаха
Дейвид Р. Филлипс
Анджали Панди
Хуан Волинь
Original Assignee
Портола Фармасьютиклз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Портола Фармасьютиклз, Инк. filed Critical Портола Фармасьютиклз, Инк.
Publication of EA200901473A1 publication Critical patent/EA200901473A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

В настоящем изобретении предлагаются способы и композиции для быстрого и обратимого подавления агрегации тромбоцитов у субъектов, нуждающихся в таком лечении, при введении соединений формулы (I) в отдельности или в комбинации с вторым агентом, которым является аспирин или тромболитический агент.
EA200901473A 2007-05-02 2008-05-02 Внутривенные и пероральные лекарственные формы прямого и обратимого ингибитора p2y12 EA200901473A1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US91564907P 2007-05-02 2007-05-02
US94792107P 2007-07-03 2007-07-03
PCT/US2008/062518 WO2008137753A2 (en) 2007-05-02 2008-05-02 Intravenous and oral dosing of a direct-acting and reversible p2y12 inhibitor

Publications (1)

Publication Number Publication Date
EA200901473A1 true EA200901473A1 (ru) 2010-06-30

Family

ID=39587015

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200901473A EA200901473A1 (ru) 2007-05-02 2008-05-02 Внутривенные и пероральные лекарственные формы прямого и обратимого ингибитора p2y12

Country Status (17)

Country Link
US (2) US20090048216A1 (ru)
EP (1) EP2079464A2 (ru)
JP (1) JP2010526101A (ru)
KR (1) KR20100029746A (ru)
CN (1) CN101795682A (ru)
AU (1) AU2008247483A1 (ru)
BR (1) BRPI0811476A2 (ru)
CA (1) CA2686203A1 (ru)
CO (1) CO6241104A2 (ru)
EA (1) EA200901473A1 (ru)
EC (1) ECSP099778A (ru)
GT (1) GT200900284A (ru)
IL (1) IL201834A0 (ru)
MA (1) MA31663B1 (ru)
MX (1) MX2009011843A (ru)
TN (1) TN2009000451A1 (ru)
WO (1) WO2008137753A2 (ru)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006311795B2 (en) * 2005-11-03 2013-01-17 Portola Pharmaceuticals, Inc. [4-(6-halo-7-substituted-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylureas and forms and methods related thereto
JP5390407B2 (ja) * 2007-03-06 2014-01-15 ノバルティス アーゲー 炎症またはアレルギー症状の処置に適する二環式有機化合物
EP2076510A2 (en) * 2007-05-02 2009-07-08 Portola Pharmaceuticals, Inc. [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylurea salts, in different crystalline forms, pharmaceutical compositions thereof, and formulations thereof, for the treatment of thrombosis and trombosis related conditions
US20090156620A1 (en) * 2007-05-02 2009-06-18 Portola Pharmaceuticals, Inc. [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylurea salts, forms and methods related thereto
US9427448B2 (en) * 2009-11-11 2016-08-30 The Medicines Company Methods of treating, reducing the incidence of, and/or preventing ischemic events
CN102271685A (zh) * 2008-12-30 2011-12-07 斯若姆博洛捷克有限公司 鉴定发展成器官功能衰竭的风险提高的危重患者的方法及用于其治疗的化合物
US10376532B2 (en) 2009-11-11 2019-08-13 Chiesi Farmaceutici, S.P.A. Methods of treating, reducing the incidence of, and/or preventing ischemic events
PL2498731T3 (pl) 2009-11-11 2020-07-13 Chiesi Farmaceutici S.P.A. Sposoby leczenia lub zapobiegania zakrzepicy w stencie
WO2011076749A2 (en) * 2009-12-23 2011-06-30 Ratiopharm Gmbh Solid pharmaceutical dosage form
EP2523657A1 (en) 2010-01-12 2012-11-21 Portola Pharmaceuticals, Inc. Pharmaceutical composition and dosage forms of elinogrel and methods of use thereof
WO2011137459A1 (en) * 2010-04-30 2011-11-03 Portola Pharmaceuticals, Inc. Dosage forms of elinogrel and methods of injectable administration thereof
US9029095B2 (en) 2010-12-01 2015-05-12 Institut National De La Sante Et De La Recherche Medicale (Inserm) Method and kits for determining platelet susceptibility to activation in a patient
EP2646434B1 (en) * 2010-12-03 2019-05-15 Portola Pharmaceuticals, Inc. Pharmaceutical compositions, dosage forms and new forms of the compound of formula (i), and methods of use thereof
MX2019009559A (es) 2017-03-15 2019-10-15 Idorsia Pharmaceuticals Ltd Administracion subcutanea de un antagonista del receptor p2y12.
KR20200018481A (ko) 2017-06-23 2020-02-19 키에시 파르마슈티시 엣스. 피. 에이. 체폐동맥 션트 혈전증의 예방 방법
CN107462648B (zh) * 2017-08-21 2019-09-27 盐城锦明药业有限公司 一种Cangrelor中间体腺苷-2-硫酮的高效液相色谱检测方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6906063B2 (en) * 2000-02-04 2005-06-14 Portola Pharmaceuticals, Inc. Platelet ADP receptor inhibitors
AU2006311795B2 (en) 2005-11-03 2013-01-17 Portola Pharmaceuticals, Inc. [4-(6-halo-7-substituted-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylureas and forms and methods related thereto

Also Published As

Publication number Publication date
EP2079464A2 (en) 2009-07-22
CO6241104A2 (es) 2011-01-20
CA2686203A1 (en) 2008-11-13
MX2009011843A (es) 2010-04-22
KR20100029746A (ko) 2010-03-17
JP2010526101A (ja) 2010-07-29
WO2008137753A2 (en) 2008-11-13
BRPI0811476A2 (pt) 2014-11-04
US20090048216A1 (en) 2009-02-19
AU2008247483A1 (en) 2008-11-13
GT200900284A (es) 2012-01-31
TN2009000451A1 (en) 2011-03-31
MA31663B1 (fr) 2010-09-01
IL201834A0 (en) 2010-06-16
CN101795682A (zh) 2010-08-04
WO2008137753A3 (en) 2009-02-12
ECSP099778A (es) 2010-01-29
US20120009172A1 (en) 2012-01-12

Similar Documents

Publication Publication Date Title
EA200901473A1 (ru) Внутривенные и пероральные лекарственные формы прямого и обратимого ингибитора p2y12
EA201270215A1 (ru) Apaf-1 ингибиторные соединения
EA201300684A1 (ru) Производные 6-амино-2-фениламино-1н-бензимидазол-5-карбоксамида и их применение в качестве ингибиторов микросомной простагландин-е2-синтазы-1
CY1119730T1 (el) Παραγωγα καρβοξυλικου οξεος πυρρολιδινης ως αγωνιστες του συζευγμενου με πρωτεϊνή-g υποδοχεα 43 (gpr43), φαρμακευτικη συνθεση και μεθοδοι για χρηση στην αντιμετωπιση μεταβολικων διαταραχων
EA200801997A1 (ru) Новые соединения
ECSP099376A (es) Inhibidores de la actividad de la akt
EA200971115A1 (ru) Новые ингибиторы обратной транскриптазы вич
MA33803B1 (fr) Inhibiteur de bromodomaine de benzodiazépine
EA201791284A1 (ru) Селективные ингибиторы cdk8/cdk19 и их применение в качестве противометастатических и химиопрофилактических агентов для лечения рака
EA200900023A1 (ru) Применение замещенных 2-аминотетралинов для изготовления лекарственного средства для предупреждения, облегчения и/или лечения разных видов боли
EA201170531A1 (ru) Соединения на основе пиридина и пиримидина в качестве ингибиторов сигнального пути wnt для лечения рака
DK1853602T3 (da) Kemiske forbindelser
DK1853588T3 (da) Kemiske forbindelser
CL2011000589A1 (es) Compuestos derivados de pirrolidin-2-carboxamida, inhibidores de la interaccion p53-mdm2; composicion farmaceutica que los comprende; y su uso en la preparacion de medicamentos utiles para el tratamiento del cancer.
GT200700060A (es) Compuestos de benzimidazolilo
EA200970156A1 (ru) Пиридизиноновые производные
EA201290184A1 (ru) Бензодиазепиновый ингибитор бромодомена
NI200700320A (es) Inhibidores de la actividad akt
EA201300200A1 (ru) N-((6-аминопиридин-3-ил)метил)гетероарилкарбоксамиды в качестве ингибиторов калликреина в плазме
UA109290C2 (uk) Спільні кристали і солі інгібіторів ccr3
ATE554084T1 (de) N-hydroxyacrylamidverbindungen
MA32727B1 (fr) Pyrazolylaminopyridines au titre d'inhibiteurs de fak
EA200900631A1 (ru) Замещённые пиразолы и триазолы, как ингибиторы кбв (кинезин-белок веретена)
NO20085317L (no) Imidazoazepinonforbindelser
EA201591175A1 (ru) Трициклические соединения в качестве ингибиторов cftr